Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting

BACKGROUND: Despite national guideline recommendations, epidermal growth factor receptor mutated (EGFRm) metastatic non‐small cell lung cancer (mNSCLC) patients may still receive suboptimal treatment in the first line (1L). This study evaluated 1L therapy initiation in relation to biomarker testing...

Descripción completa

Detalles Bibliográficos
Autores principales: Apple, Jon, Shenolikar, Rahul, De Silva, Kevin, Sun, Ping, Spira, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315796/
https://www.ncbi.nlm.nih.gov/pubmed/37306623
http://dx.doi.org/10.1002/cam4.6052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315796/
https://www.ncbi.nlm.nih.gov/pubmed/37306623
http://dx.doi.org/10.1002/cam4.6052

Ejemplares similares